SalvaRx's (SALV) long term aim is to develop a pipeline of complementary cancer immunotherapy-focused products and technologies, activating the body's immune system to down-regulate tumour progression. Achieving a durable patient response to support long-term survival is essential for Pharma companies scouting new clinical assets. SALV's expanding product portfolio continues to create a substantial licensing or exit opportunity for investors.
16 Sep 2016
Diversifying portfolio spreads the risk
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Diversifying portfolio spreads the risk
Salvarx Group (SALV:LON) | 0 0 (-8.6%) | Mkt Cap: 6.74m
- Published:
16 Sep 2016 -
Author:
Lucy Williams -
Pages:
13
SalvaRx's (SALV) long term aim is to develop a pipeline of complementary cancer immunotherapy-focused products and technologies, activating the body's immune system to down-regulate tumour progression. Achieving a durable patient response to support long-term survival is essential for Pharma companies scouting new clinical assets. SALV's expanding product portfolio continues to create a substantial licensing or exit opportunity for investors.